uniQure
uniQure is delivering on the promise of gene therapy -- single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary and partnered gene therapies to treat patients with hemophilia, Huntington’s disease and other severe genetic diseases.
Leadership
Matt Kapusta
CEO
![](https://h.plus/wp-content/uploads/2021/06/MattKapusta.jpeg)
Financial Performance
Funding
Raised Capital
Year
Type
Offered / Sold Amount
Filings
Reported by Press*
Round
2012
7.8M USD
Series A
2013
79.25M USD
Series B
2014
91.8M USD
Post-IPO Equity
Known Investors
Name
Type
HQ
Other Relevant Investments
Venture Capital
United Kingdom
Corporation
Italy
Government Agency
Switzerland
Venture Capital
Netherlands
Venture Capital
Netherlands
Investment Bank
Germany
*More data available at: [CB Insights] [CrunchBase] [PitchBook]
Related
News
News